These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 37334773)
1. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL). Visram A; Hayman SR; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Warsame R; Kourelis T; Cook J; Binder M; Gonsalves W; Muchtar E; Leung N; Roy V; Rajkumar SV; Kumar S Am J Hematol; 2023 Aug; 98(8):1277-1285. PubMed ID: 37334773 [TBL] [Abstract][Full Text] [Related]
2. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221 [TBL] [Abstract][Full Text] [Related]
3. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma. Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107 [TBL] [Abstract][Full Text] [Related]
4. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631 [TBL] [Abstract][Full Text] [Related]
5. Final outcomes of escalated melphalan 280 mg/m Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806 [TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 Trial of Carfilzomib Plus High-Dose Melphalan Preparative Regimen for Salvage Autologous Hematopoietic Cell Transplantation Followed by Maintenance Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma. Costa LJ; Landau HJ; Chhabra S; Hari P; Innis-Shelton R; Godby KN; Hamadani M; Tamari R; Anderton K; Dixon P; Giralt SA Biol Blood Marrow Transplant; 2018 Jul; 24(7):1379-1385. PubMed ID: 29410301 [TBL] [Abstract][Full Text] [Related]
7. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312 [TBL] [Abstract][Full Text] [Related]
8. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Nieto Y; Valdez BC; Pingali SR; Bassett R; Delgado R; Nguyen J; Shah N; Popat U; Jones RB; Andersson BS; Gulbis A; Ahmed S; Bashir Q; Parmar S; Patel K; Myers A; Rondon G; Orlowski RZ; Champlin R; Qazilbash M Lancet Haematol; 2017 Jun; 4(6):e283-e292. PubMed ID: 28522110 [TBL] [Abstract][Full Text] [Related]
9. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study. Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830 [TBL] [Abstract][Full Text] [Related]
10. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081 [TBL] [Abstract][Full Text] [Related]
11. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375 [TBL] [Abstract][Full Text] [Related]
12. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Abidi MH; Agarwal R; Ayash L; Deol A; Al-Kadhimi Z; Abrams J; Cronin S; Ventimiglia M; Lum L; Zonder J; Ratanatharathorn V; Uberti J Biol Blood Marrow Transplant; 2012 Sep; 18(9):1455-61. PubMed ID: 22453252 [TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
14. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma. Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842 [TBL] [Abstract][Full Text] [Related]
15. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study. Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK; Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603 [TBL] [Abstract][Full Text] [Related]
16. Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma. Hagen P; Norton J; Tsai S; Campo L; Lee M; Gomez K; Stiff P Br J Haematol; 2024 Apr; 204(4):1422-1428. PubMed ID: 38176404 [TBL] [Abstract][Full Text] [Related]
17. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251 [TBL] [Abstract][Full Text] [Related]
18. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035 [TBL] [Abstract][Full Text] [Related]
19. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients. Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717 [TBL] [Abstract][Full Text] [Related]
20. Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). Roussel M; Moreau P; Huynh A; Mary JY; Danho C; Caillot D; Hulin C; Fruchart C; Marit G; Pégourié B; Lenain P; Araujo C; Kolb B; Randriamalala E; Royer B; Stoppa AM; Dib M; Dorvaux V; Garderet L; Mathiot C; Avet-Loiseau H; Harousseau JL; Attal M; Blood; 2010 Jan; 115(1):32-7. PubMed ID: 19884643 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]